Altrius Capital Management Inc increased its holdings in shares of Roche Holding AG (OTCMKTS:RHHBY – Free Report) by 6.0% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 224,804 shares of the company’s stock after purchasing an additional 12,646 shares during the period. Roche accounts for 2.0% of Altrius Capital Management Inc’s holdings, making the stock its 12th biggest holding. Altrius Capital Management Inc’s holdings in Roche were worth $7,794,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of the business. Archer Investment Corp boosted its position in Roche by 10.6% during the second quarter. Archer Investment Corp now owns 6,810 shares of the company’s stock valued at $236,000 after purchasing an additional 652 shares in the last quarter. Rhumbline Advisers grew its position in shares of Roche by 0.9% in the 2nd quarter. Rhumbline Advisers now owns 103,985 shares of the company’s stock worth $3,605,000 after buying an additional 904 shares during the last quarter. Waldron Private Wealth LLC bought a new position in shares of Roche during the 2nd quarter worth approximately $263,000. Hantz Financial Services Inc. purchased a new stake in Roche during the second quarter valued at approximately $1,164,000. Finally, Lee Danner & Bass Inc. purchased a new position in Roche in the second quarter worth $327,000.
Roche Stock Up 0.7 %
OTCMKTS RHHBY opened at $39.61 on Thursday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.35 and a quick ratio of 1.04. The stock’s fifty day moving average price is $39.89 and its 200 day moving average price is $34.97. Roche Holding AG has a 1 year low of $29.20 and a 1 year high of $42.43.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on RHHBY
Roche Company Profile
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
Further Reading
- Five stocks we like better than Roche
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- How Much Can You Make in Stocks in One Month?
- Market Cap Calculator: How to Calculate Market Cap
- This Is the Top Large-Cap Stock Insiders Are Buying
- How to Start Investing in Real Estate
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.